Press Release: MapmyGenome Launches Cardiomap™ Genetics Test to Predict Heart Disease and Diabetes
Hyderabad, India — September 29, 2013 (World Heart Day): MapmyGenome announced the launch of Cardiomap™ — a genetics-based cardiac health profile — on World Heart Day. This test reports genetic predisposition to heart diseases, diabetes, and associated risk factors, along with best-fit risk mitigation options such as drug responses and lifestyle changes.
“Considering the increasing numbers of cases with cardiovascular diseases and diabetes, we felt that an affordable predictive test was the need of the hour. Cardiomap™ is the route map to fight diabetes, heart disease, and many other lifestyle conditions.” — Anu Acharya, CEO, MapmyGenome
About Cardiomap™
Cardiomap™ is MapmyGenome’s genetic test for cardiac health. It covers many heart diseases and metabolic disorders, including genetic predisposition to lipid levels, blood pressure, QT interval, alcohol and nicotine dependence, and obesity. The risk management section features nutrition, fitness, and key drug responses. Cardiomap™ enables:
Prevention of heart disease and diabetes by managing associated risk conditions
Early detection in consultation with medical experts
Selection of best-fit treatment from analysis of individual drug responses
About MapmyGenome
MapmyGenome is India’s pioneering personal genomics company with a vision to provide “Better Health for Indians using technology.” Their portfolio includes Genomepatri™, Cardiomap™, and brain wellness solutions under Mapmybrain™.
Know Your Heart Disease Risk Genetically
Cardiomap™ by MapmyGenome screens for genetic predisposition to heart disease, diabetes, cholesterol, hypertension, and more — with personalised drug response insights and certified genetic counselling included.
